Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity

Journal of Clinical Investigation

Volumn 118, Issue 5, 2008, Pages 1750-1764

  Tiedemann, Rodger E ^a   Mao, Xinliang ^b,c   Shi, Chang Xin ^a   Yuan, Xiao Zhu ^a   Palmer, Stephen E ^a   Sebag, Michael ^a   Marler, Ron ^a   Chesi, Marta ^a   Fonseca, Rafael ^a   Bergsagel, P Leif ^a   Schimmer, Aaron D ^b,c,d   Stewart, A Keith ^a  

^a MAYO CLINIC   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c McLaughlin Centre for Molecular Medicine   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE KINASE; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; CYCLIN D1; CYCLIN D2; CYTOKININ; DEXAMETHASONE; DIHYDROGAMBOGIC ACID; GAMBOGIC ACID; KINETIN RIBOSIDE; LENTIVIRUS VECTOR; PHOSPHOPROTEIN PHOSPHATASE 2A; PRISTIMERIN; TRANSCRIPTION FACTOR MAF;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; GROWTH DISORDER; HUMAN; HUMAN CELL; IC 50; LOW DRUG DOSE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REPEATED DRUG DOSE; RNA INTERFERENCE; TRANSACTIVATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CYCLINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; KINETIN; LENTIVIRUS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; MULTIPLE MYELOMA; NIH 3T3 CELLS; NUCLEOSIDES; PROMOTER REGIONS (GENETICS); RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 43049143874     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34149     Document Type: Article

References (56)

1. [No authors listed]. 2004. Cancer facts and figures 2004. American Cancer Society. Atlanta, Georgia, USA. 58 pp.
2. Bergsagel, P.L., et al. 2005. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 106:296-303.
3. Koziczak, M., Holbro, T., and Hynes, N.E. 2004. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene. 23:3501-3508.
4. Kozar, K., et al. 2004. Mouse development and cell proliferation in the absence of D-cyclins. Cell. 118:477-491.
5. Malumbres, M., et al. 2004. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 118:493-504.
6. Kozar, K., and Sicinski, P. 2005. Cell cycle progression without cyclin D-CDK4 and cyclin D-CDK6 complexes. Cell Cycle. 4:388-391.
7. Lahti, J.M., Li, H., and Kidd, V.J. 1997. Elimination of cyclin D1 in vertebrate cells leads to an altered cell cycle phenotype, which is rescued by overexpression of murine cyclins D1, D2, or D3 but not by a mutant cyclin D1. J. Biol. Chem. 272:10859-10869.
8. Carthon, B.C., et al. 2005. Genetic replacement of cyclin D1 function in mouse development by cyclin D2. Mol. Cell. Biol. 25:1081-1088.
9. Ciemerych, M.A., et al. 2002. Development of mice expressing a single D-type cyclin. Genes Dev. 16:3277-3289.
10. Sicinski, P., et al. 1996. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature. 384:470-474.
11. Hurt, E.M., et al. 2004. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 5:191-199.
12. Mao, X., et al. 2007. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood. 110:4047-4054.
13. National Toxicology Program. 1986. NTP Toxicology and Carcinogenesis Studies of C.I. Basic Red 9 Monohydrochloride (Pararosaniline) (CAS 569-61-9) In F344/N Rats and B6C3F1 Mice (Feed Studies). Natl. Toxicol. Program Tech. Rep. Ser. 285:1-228.
14. Au, W., Butler, M.A., Bloom, S.E., and Matney, T.S. 1979. Further study of the genetic toxicity of gentian violet. Mutat. Res. 66:103-112.
15. Hennequin, C., Giocanti, N., Balosso, J., and Favaudon, V. 1994. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res. 54:1720-1728.
16. Shao, R.G., et al. 1997. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. 57:4029-4035.
17. Pandey, M.K., et al. 2007. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-{kappa}B signaling pathway. Blood. 110:3517-3525.
18. Yore, M.M., Liby, K.T., Honda, T., Gribble, G.W., and Sporn, M.B. 2006. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl] imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol. Cancer Ther. 5:3232-3239.
19. Werner, T., Motyka, V., Strnad, M., and Schmulling, T. 2001. Regulation of plant growth by cytokinin. Proc. Natl. Acad. Sci. U. S. A. 98:10487-10492.
20. Gray, W.M. 2004. Hormonal regulation of plant growth and development. PLoS Biol. 2:e311.
21. Riou-Khamlichi, C., Huntley, R., Jacqmard, A., and Murray, J.A. 1999. Cytokinin activation of Arabidopsis cell division through a D-type cyclin. Science. 283:1541-1544.
22. Guo, Y., Harwalkar, J., Stacey, D.W., and Hitomi, M. 2005. Destabilization of cyclin D1 message plays a critical role in cell cycle exit upon mitogen withdrawal. Oncogene. 24:1032-1042.
23. Jourdan, M., et al. 1998. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br. J. Haematol. 100:637-646.
24. Muniz, L.C., Yehia, G., Memin, E., Ratnakar, P.V., and Molina, C.A. 2006. Transcriptional Regulation of Cyclin D2 by the PKA Pathway and Inducible cAMP Early Repressor (ICER) in Granulosa Cells. Biol. Reprod. 75:279-288.
25. Silverstein, A.M., Barrow, C.A., Davis, A.J., and Mumby, M.C. 2002. Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc. Natl. Acad. Sci. U. S. A. 99:4221-4226.
26. Krieger, S., Grunau, C., Sabbah, M., and Sola, B. 2005. Cyclin D1 gene activation in human myeloma cells is independent of DNA hypomethylation or histone hyperacetylation. Exp. Hematol. 33:652-659.
27. Muto, A., et al. 2002. Activation of Maf/AP-1 repressor Bach2 by oxidative stress promotes apoptosis and its interaction with promyelocytic leukemia nuclear bodies. J. Biol. Chem. 277:20724-20733.
28. Muto, A., et al. 1998. Identification of Bach2 as a B-cell-specific partner for small maf proteins that negatively regulate the immunoglobulin heavy chain gene 3′ enhancer. EMBO J. 17:5734-5743.
29. White, P.C., et al. 2006. Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes. Oncogene. 25:2170-2180.
30. Razavi, R., Ramos, J.C., Yehia, G., Schlotter, F., and Molina, C.A. 1998. ICER-IIgamma is a tumor suppressor that mediates the antiproliferative activity of cAMP. Oncogene. 17:3015-3019.
31. Molina, C.A., Foulkes, N.S., Lalli, E., and Sassone-Corsi, P. 1993. Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell. 75:875-886.
32. Laoide, B.M., Foulkes, N.S., Schlotter, F., and Sassone-Corsi, P. 1993. The functional versatility of CREM is determined by its modular structure. EMBO J. 12:1179-1191.
33. Stehle, J.H., et al. 1993. Adrenergic signals direct rhythmic expression of transcriptional repressor CREM in the pineal gland. Nature. 365:314-320.
34. Herber, B., Truss, M., Beato, M., and Muller, R. 1994. Inducible regulatory elements in the human cyclin D1 promoter. Oncogene. 9:1295-1304.
35. Moriuchi, A., et al. 2003. A CRE and the region occupied by a protein induced by growth factors contribute to up-regulation of cyclin D1 expression in hepatocytes. Biochem. Biophys. Res. Commun. 300:415-421.
36. Kim, M.J., et al. 2006. Exendin-4 induction of cyclin D1 expression in INS-1 beta-cells: involvement of cAMP-responsive element. J. Endocrinol. 188:623-633.
37. Cooper, A.B., et al. 2006. A unique function for cyclin D3 in early B cell development. Nat. Immunol. 7:489-497.
38. Griffaut, B., Bos, R., Maurizis, J.C., Madelmont, J.C., and Ledoigt, G. 2004. Cytotoxic effects of kinetin riboside on mouse, human and plant tumour cells. Int. J. Biol. Macromol. 34:271-275.
39. Honma, Y., and Ishii, Y. 2002. Differentiation of human myeloid leukemia cells by plant redifferentiation-inducing hormones. Leuk. Lymphoma. 43:1729-1735.
40. Ishii, Y., Hori, Y., Sakai, S., and Honma, Y. 2002. Control of differentiation and apoptosis of human myeloid leukemia cells by cytokinins and cytokinin nucleosides, plant redifferentiation-inducing hormones. Cell Growth Differ. 13:19-26.
41. Sakane-Ishikawa, E., et al. 2005. Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. J. Clin. Oncol. 23:8012-8017.
42. Muto, A., et al. 2004. The transcriptional programme of antibody class switching involves the repressor Bach2. Nature. 429:566-571.
43. Kamio, T., et al. 2003. B-cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs. Blood. 102:3317-3322.
44. Ge, L., et al. 2005. Identification of kinetin and kinetin riboside in coconut (Cocos nucifera L.) water using a combined approach of liquid chromatography-tandem mass spectrometry, high performance liquid chromatography and capillary electrophoresis. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 829:26-34.
45. Barciszewski, J., Mielcarek, M., Stobiecki, M., Siboska, G., and Clark, B.F. 2000. Identification of 6-furfuryladenine (kinetin) in human urine. Biochem. Biophys. Res. Commun. 279:69-73.
46. Epstein, H.A. 2004. Kinerase: the science behind the technology. Skinmed. 3:339.
47. Glaser, D.A., and Rogers, C. 2001. Topical and systemic therapies for the aging face. Facial Plast. Surg. Clin. North Am. 9:189-196.
48. Kligman, D. 2000. Cosmeceuticals. Dermatol. Clin. 18:609-615.
49. Root, D.E., Hacohen, N., Hahn, W.C., Lander, E.S., and Sabatini, D.M. 2006. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat. Methods. 3:715-719.
50. Naldini, L., et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272:263-267.
51. Brooks, A.R., Shiffman, D., Chan, C.S., Brooks, E.E., and Milner, P.G. 1996. Functional analysis of the human cyclin D2 and cyclin D3 promoters. J. Biol. Chem. 271:9090-9099.
52. Krajewski, S., Zapata, J.M., and Reed, J.C. 1996. Detection of multiple antigens on Western blots. Anal. Biochem. 236:221-228.
53. Keats, J.J., et al. 2007. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 12:131-144.
54. Shi, C.X., Graham, F.L., and Hitt, M.M. 2006. A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter. J. Gene Med. 8:442-451.
55. Birney, E., et al. 2006. Ensembl 2006. Nucleic Acids Res. 34:D556-D561.
56. Ashurst, J.L., et al. 2005. The Vertebrate Genome Annotation (Vega) database. Nucleic Acids Res. 33:D459-D465.